TABLE 1.

PCR primers

Primer specificity	Primer sequences (human)a
ASNS, mRNA	FP 5′-GCAGCTGAAAGAAGCCCAAGT-3′
	RP 5′-TGTCTTCCATGCCAATTGCA-3′
GCN2, mRNA	FP 5′-GAAATGGTAAACATCGGGCAAACTC-3′
	RP 5′-TTCACAAGAGCCAGGAGAATCTTCAC-3′
GAPDH, mRNA	FP 5′-TTGGTATCGTGGAAGGACTC-3′
	RP 5′-ACAGTCTTCTGGGTGGCAGT-3′
VEGF-A, mRNA	FP 5′-ACTGAGGAGTCCAACATCAC-3′
	RP 5′-CTTGTCTTGCTCTATCTTTC-3′
EGR1, mRNA	FP 5′-AGAAGGACAAGAAAGCAGACAAAAGTGT-3′
	RP 5′-GGGGACGGGTAGGAAGAGAG-3′
EGR1, transcription activity	FP 5′-CTACGAGCACCTGACCGCAGG-3′
	RP 5′-ACAGGACGCCAGGATGGTGG-3′
EGR1 P1, ChIP assay	FP 5′-CCCCGTCTCAGAAAGAATAAAAACATTA-3′
	RP 5′-CCTTGTGTCTGAATGTCCATTTTGC-3′
EGR1 P2, ChIP assay	FP 5′-CCTCTTTCGGATTCCCGCAG-3′
	RP 5′-GGTCCTTGTGGTGAGGGGTCA-3′
EGR1 P3, ChIP assay	FP 5′-GAGGGAGCGAGGGAGCAACC-3′
	RP 5′-CTCCAAATAAGGTGCTGCCCAAA-3′
EGR1 P4, ChIP assay	FP 5′-CATATTAGGGCTTCCTGCTTCCCATA-3′
	RP 5′-CCGCCTCTATTTGAAGGGTCTGG-3′
EGR1 P5, ChIP assay	FP 5′-GTCACGACGGAGGCGGACC-3′
	RP 5′-CGGCGGCTCCCCAAGTTC-3′
EGR1 P6, ChIP assay	FP 5′-CGCAGAGGACCGAGCTTTTGT-3′
	RP 5′-GCAGCCCCGCTCATCAAAA-3′
EGR1 P7, ChIP assay	FP 5′-GGGGATTCTCCGTATTTGCGTC-3′
	RP 5′-GGCTACCATTGACTCCCGAGGT-3′
EGR1 P8, ChIP assay	FP 5′-GTCCCAGCTCATCAAACCCAGC-3′
	RP 5′-AGAAGCGGCGATCACAGGACTC-3′
VEGF-A upstream, ChIP assay	FP 5′-ACTTTCCTGCTCCCTCCTCGC-3′
	RP 5′-CCACCAAGGTTCACAGCCTG-3′
VEGF-A promoter, ChIP assay	FP 5′-CGCTCGGTGCTGGAATTTGATA-3′
	RP 5′-TGGGGAATGGCAAGCAAAAA-3′
VEGF-A intron 1, ChIP assay	FP 5′-GCTGTCACTGCCACTCGGTCTC-3′
	RP 5′-GCAGCAATCCACCCCAAAAC-3′
VEGF-A intron 4, ChIP assay	FP 5′-GTGAGGATGTAGTCACGGATTC-3′
	RP 5′-CCAAAGGTCACATAGCGGGA-3′
JNK1, mRNA	FP 5′-CCATTTCAGAATCAGACTCATGCCA-3′
	RP 5′-TGTGGTGTGAAAACATTCAAAAGGC-3′
JNK2, mRNA	FP 5′-GGGATTGTTGTGCTGCATTTGATAC-3′
	RP 5′-TGGTTCTGAAAAGGACGGCTTAGTTT-3′
ERK1, mRNA	FP 5′-CGCTTCCGCCATGAGAATGTC-3′
	RP 5′-CAGGTCAGTCTCCATCAGGTCCTG-3′
ERK2, mRNA	FP 5′-CGTGTTGCAGATCCAGACCATGAT-3′
	RP 5′-TGGACTTGGTGTAGCCCTTGGAA-3′
ATF3, mRNA	FP 5′-GAGCGGAGCCTGGAGCAAAA-3′
	RP 5′-GGGGACGATGGCAGAAGCACT-3′

^a FP, forward primer; RP, reverse primer.